Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the…
Browsing: Breast
Breast Cancer
Yen-Shen Lu, MD of National Taiwan University discusses Ribociclib and the Primary results from the randomized Phase II RIGHT Choice…
RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and…
Getting description
Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a…
HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022Aditya Bardia, MD of Mass General discusses theGS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan…
Trastuzumab emtansine versus Trastuzumab deruxtecan versus in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase…
Trastuzumab deruxtecan DESTINY-Breast02 results presented at SABCS 2022 with Ian E. Krop, MD, PhD Yale School of Medicine.GS2-01: Trastuzumab deruxtecan…
SABCS 2022 Day 2 Press Conference December 7, 2022. Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan…
iFrame is not supported! Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT…
Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial…
iFrame is not supported! Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a…
Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that…
7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to…
7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to…
Breast Density Notification Rule: 2022 FDA: Dense Breasts The FDA Is Updating the Notification Rule For Women With Dense…
Male Breast Cancer: Clinical Signs [2022] What Are the Signs of Male Breast Cancer? And why do they go…
Male Breast Cancer: Clinical Signs [2022] iFrame is not supported! What Are the Signs of Male Breast Cancer? And why…
Breast Density Notification Rule: 2022 FDA: Dense Breasts iFrame is not supported! The FDA Is Updating the Notification Rule For…
Prioritizing Screening Mammogram: Help Early Diagnosis? Mammography (breast imaging) is one of the most commonly used preventive healthcare services (annual…
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series…
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel…
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test…
Breast Cancer Screening [2022]: What Are We Missing? Are Women Avoiding Breast Cancer Screening? Because of COVID-19 and the subsequent…
Question and Answer Session Kay Yeung, MD, Ph.D. – ASCO [2022] Breast Cancer In-Depth Slides: MOASC https://oncologytube.com/v/41294 Kay Yeung, MD,…
ASCO [2022] Breast Cancer In-Depth Slides: MOASC Â Kay Yeung, MD, Ph.D. Delivers Her MOASC 2022 Breast Cancer Presentation Hello,…
ASCO 2022 Breast Cancer Overview: MOASC Spotlight  DESTINY-Breast04 Data from ASCO 2022 Annual Meeting I presented a lot of…
Olaparib Approved In Japan: Breast Cancer  Olaparib’s Study Design For BRCA1 or BRC2 Variants in Early Breast Cancer OlympiA…
T-DXd HER2-Positive Breast Cancer: DESTINY-Breast03 DESTINY-Breast03 Phase 3 clinical trial Study Design for HER2-Positive Breast Cancer This was a safety…
In this panel discussion and workshop, experts from the University of Chicago Medicine and the University of Illinois Cancer Center…
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiation treatment experiences…
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates among racial/ethnic groups.…
Listen as Amanda Kaczerski and Mahire Bonomo, Executive Director at the Center for Continuing Medical Education at The University of…
The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how…
Dr. John Stewart from the Louisiana State University School of Medicine discusses navigating complex treatment. The University of Chicago Medicine…
The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how…
Dr. Monical Peek from The University of Chicago discusses women’s fears and racial health inequities as part of a quality…
The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how…
Dr. Nan Chen from the University of Chicago Medicine shares a status update from ASCO on the quality improvement program…
Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC)…
This study led us to the discovery of 53 gene signatures called IMPRINT and with the data we used to…
So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any…
So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any…
 Article: Transcript: Question – Please Tell Us About The AMEERA-6 Trial  So, I’m talking about AMEERA-6 which is…
Audio: So the I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer…
Pathologic Complete Response: How may the I-SPY2 trial help HR positive HER2 negative Breast Cancer patients? Laura Huppert By Laura…
Transcript: So the I-SPY2Â trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer…
Audio: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously…
Video: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously…
Transcript – Where is the Elaine 2 Study and Just-in-time Model Right Now? – Article Question – Please Tell Us…